{"name":"Cephalon","slug":"cephalon","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2811057000,"revenueGrowth":28.2,"grossMargin":0,"rdSpend":0,"netIncome":425745000,"cash":4891833000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2010"},"revenueBreakdown":[],"timeline":[{"date":"1997-01-01","label":"Gabitril first approved","drug":"Gabitril","drugSlug":"tiagabine","type":"approval","sentiment":"positive"},{"date":"2000-01-01","label":"Trisenox first approved","drug":"Trisenox","drugSlug":"arsenic-trioxide","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"ACTIQ®","genericName":"ACTIQ®","slug":"actiq","indication":"Breakthrough cancer pain in adults who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain","status":"phase_2"},{"name":"Free doxorubicin hydrochloride","genericName":"Free doxorubicin hydrochloride","slug":"free-doxorubicin-hydrochloride","indication":"Breast cancer","status":"phase_2"},{"name":"ORAVESCENT Fentanyl Citrate","genericName":"ORAVESCENT Fentanyl Citrate","slug":"oravescent-fentanyl-citrate","indication":"Breakthrough pain in opioid-tolerant cancer patients","status":"phase_3"},{"name":"OraVescent fentanyl (OVF)","genericName":"OraVescent fentanyl (OVF)","slug":"oravescent-fentanyl-ovf","indication":"Breakthrough pain in opioid-tolerant cancer patients","status":"phase_3"},{"name":"Trisenox","genericName":"ARSENIC TRIOXIDE","slug":"arsenic-trioxide","indication":"Acute myelomonocytic leukemia, FAB M4","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"CEP-10953 (Armodafinil)","genericName":"CEP-10953 (Armodafinil)","slug":"cep-10953-armodafinil","indication":"Narcolepsy","status":"phase_3"},{"name":"Gabitril","genericName":"Gabitril","slug":"gabitril","indication":"Other","status":"marketed"},{"name":"Liposomal doxorubicin hydrochloride","genericName":"Liposomal doxorubicin hydrochloride","slug":"liposomal-doxorubicin-hydrochloride","indication":"Other","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Effentora®","genericName":"Effentora®","slug":"effentora","indication":"Treatment of opioid-induced constipation","status":"phase_2"},{"name":"Fentanyl Buccal Tablet (FBT)","genericName":"Fentanyl Buccal Tablet (FBT)","slug":"fentanyl-buccal-tablet-fbt","indication":"Pain","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Gabitril","genericName":"TIAGABINE","slug":"tiagabine","indication":"Partial seizures","status":"marketed"}]}],"pipeline":[{"name":"ACTIQ®","genericName":"ACTIQ®","slug":"actiq","phase":"phase_2","mechanism":"ACTIQ® delivers fentanyl, a potent opioid analgesic, directly to the oral mucosa for rapid absorption and pain relief.","indications":["Breakthrough cancer pain in adults who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain"],"catalyst":""},{"name":"CEP-10953 (Armodafinil)","genericName":"CEP-10953 (Armodafinil)","slug":"cep-10953-armodafinil","phase":"phase_3","mechanism":"Armodafinil promotes wakefulness by increasing dopamine levels in the brain, likely through dopamine reuptake inhibition and other monoaminergic pathways.","indications":["Narcolepsy","Obstructive sleep apnea","Shift work sleep disorder","Excessive daytime sleepiness"],"catalyst":""},{"name":"Effentora®","genericName":"Effentora®","slug":"effentora","phase":"phase_2","mechanism":"A selective kappa opioid receptor antagonist.","indications":["Treatment of opioid-induced constipation"],"catalyst":""},{"name":"Fentanyl Buccal Tablet (FBT)","genericName":"Fentanyl Buccal Tablet (FBT)","slug":"fentanyl-buccal-tablet-fbt","phase":"marketed","mechanism":"Mu-opioid receptor (MOR)","indications":[],"catalyst":""},{"name":"Free doxorubicin hydrochloride","genericName":"Free doxorubicin hydrochloride","slug":"free-doxorubicin-hydrochloride","phase":"phase_2","mechanism":"Doxorubicin hydrochloride intercalates DNA and inhibits topoisomerase II, leading to DNA damage and cell death.","indications":["Breast cancer","Ovarian cancer","Lung cancer","Leukemia","Lymphoma"],"catalyst":""},{"name":"Gabitril","genericName":"Gabitril","slug":"gabitril","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Gabitril","genericName":"TIAGABINE","slug":"tiagabine","phase":"marketed","mechanism":"Sodium- and chloride-dependent GABA transporter 1","indications":["Partial seizures"],"catalyst":""},{"name":"Liposomal doxorubicin hydrochloride","genericName":"Liposomal doxorubicin hydrochloride","slug":"liposomal-doxorubicin-hydrochloride","phase":"marketed","mechanism":"DNA and topoisomerase II","indications":[],"catalyst":""},{"name":"ORAVESCENT Fentanyl Citrate","genericName":"ORAVESCENT Fentanyl Citrate","slug":"oravescent-fentanyl-citrate","phase":"phase_3","mechanism":"Fentanyl citrate binds to opioid receptors in the central nervous system to produce analgesia and sedation.","indications":["Breakthrough pain in opioid-tolerant cancer patients"],"catalyst":""},{"name":"OraVescent fentanyl (OVF)","genericName":"OraVescent fentanyl (OVF)","slug":"oravescent-fentanyl-ovf","phase":"phase_3","mechanism":"OraVescent fentanyl is a rapid-onset opioid agonist delivered via an effervescent oral formulation that enhances buccal absorption of fentanyl for fast pain relief.","indications":["Breakthrough pain in opioid-tolerant cancer patients"],"catalyst":""},{"name":"Trisenox","genericName":"ARSENIC TRIOXIDE","slug":"arsenic-trioxide","phase":"marketed","mechanism":"Potassium voltage-gated channel subfamily H member 2","indications":["Acute myelomonocytic leukemia, FAB M4","Acute promyelocytic leukemia, FAB M3"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNZW1wRWVscTQ4MW9CaUUyR1UxdjY5RTJraHFiYllYNzY3Q251Sk5EX21sMVd4V3BVM2xiU244anBwNWE5U3I1VWRZWWU3S1k0M1BGX0ZoX0JkX0Z1YkMxbzBiZVBpb2JORTRab1N3OElUNmRRNFRzU3d2a2VhejRzbU1QUkFyaWVrdkhuZWdUem1WMEh0ajhKMUtUUFg5REVUbl9TdmhORHoyOXV2S1dydjJ0OHRCRjVYNWFYLS14UEd2cXdodlZoaHh2ZVhES0lpVjdXOE1Ma3dyaVdpRXFIRmUzVQ?oc=5","date":"2025-12-09","type":"patent","source":"legalblogs.wolterskluwer.com","summary":"Pay-for-Delay: The CJEU Confirms Teva/Cephalon and Defines the Limits of Patent Settlement Agreements - legalblogs.wolterskluwer.com","headline":"Pay-for-Delay: The CJEU Confirms Teva/Cephalon and Defines the Limits of Patent Settlement Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNWEpJTFZMTHA4NmVvWmtmVXUzOXM3TjYxWDFLNEhReUVxaTZKbjFRU25fa2VsTTZ5aUl0WXl1dWh3Z2hiRWRtOTRUWU1KV2dqSXFYelNRTHZKQUZyZHZuUTMwem5QbVVsN0tmN181MHBMWVFEQTV3TGhIdmcxU0FIMFdkekIxUkZrbUdGUG5GV3kwMVNFWVNxVGNTYjRDNGQyWmRtZHBZRW0tZnRXdktqRlpkcDZGdDRqcnRtazRxSzhMZUhFb1l5RFkyNXZ1NjBHMmZybmw1ZUhlQl9xeFFaY3hPdEJmMGVTaVQ0WUl0Z3JDWTVYR1JNSWFVY1VCZ3B3SWxTRFpwQURjR0NoTUhFendjaV9rNkdpdVV2SHkwaUI?oc=5","date":"2025-11-05","type":"regulatory","source":"Slaughter and May","summary":"Competition and Regulatory Newsletter: European Court of Justice upholds European Commission fine for Teva and Cephalon in “pay-for-delay” case - Slaughter and May","headline":"Competition and Regulatory Newsletter: European Court of Justice upholds European Commission fine for Teva and Cephalon ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPU0pDd0xHLU51Njh2NjVzVVA3aGJHeVdVTm5seWtUVEtXUlkzYy11YUt1UE1sdUExaExfY1phdVdDRG5jZVZyelA0TGxkTTdKclRYT05qS3R3QXpYajhtOHV2SzdOdWY5cXFabVZaN2ZKb0hTLWNBcUEtV1BTWkNvUnBleGI2a2FKQV9yOGhaNzBjRlFVbnJHdUV5M2ZmTWRlNy1kSFkwNWozMXdyYjJaSUxjV3pFRFlhemUzTDZxQ0tRRTlBa0VDLUc2WlgxX3d4VC1kVU94SzA3SmNXRFRkTlhicFh6eEVFX2Q5aVMtWUZSOHdfY1Vj?oc=5","date":"2023-10-18","type":"pipeline","source":"Cleary Antitrust Watch","summary":"Teva And Cephalon v. Commission (Case T-74/21): The General Court Continues To Uphold Pay-For-Delay Infringement Decisions - Cleary Antitrust Watch","headline":"Teva And Cephalon v. Commission (Case T-74/21): The General Court Continues To Uphold Pay-For-Delay Infringement Decisio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOanRLcUM3WmZjcDBHbmdORlIyQ2RWYkQyMl9sQjVBdTRzakNHS1d5S3JpazJsMHhXWHpINE9lc3dMVTRrWjZ6b2h1UHhYNGFYWXR1UTM5MWtTcy1jTEk1VzhqdW1FcEh0QXZzZzljVEduRTFxZkNOZ1diRXE2emV3R0t5OHFjQ2FMN0ptenF1ak9JbzhVTk9kU1ZJTHMyNGxvU1dXUWVlcWNoRUNYOXlIc3BoaWM5Zw?oc=5","date":"2021-08-24","type":"pipeline","source":"topclassactions.com","summary":"Cephalon Settles FTC’s Provigil Pay-For-Delay Lawsuit for $1.2B - topclassactions.com","headline":"Cephalon Settles FTC’s Provigil Pay-For-Delay Lawsuit for $1.2B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFBxcV9ucmpXVjNUNXNFUDAtbWt5aVhrcFVaYXNYZkN4WnMwX3diSEJUSkVSU3k3WEZ5RU5LNWw1Z2FXM25qc3JYRkJOQUpmcjBSeDUtVmZCb3Y1V3UtNTNia1h2dWh0Zm1LTURvUWNIUGpCQQ?oc=5","date":"2020-11-25","type":"patent","source":"European Commission","summary":"Antitrust: Commission fines Teva and Cephalon €60.5 million for delaying entry of cheaper generic medicine - European Commission","headline":"Antitrust: Commission fines Teva and Cephalon €60.5 million for delaying entry of cheaper generic medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPamZPUmRfNlhXeUt3Ym0wQkw2NF8xbUI3NWpYMUY0NDRxLU8zaFY0OHdxRnVmckFGQlZ4T1ZYVXdrSjkwaXJVaWxjS0pzSUVnWktlSXdwZmVqZXdmODN0Y200dW1qb08wV2xlZnpSTE00M1lxT2tpcGJLMloza0FvNDFlY1ZwN3prZ3BYby13ZFVsWFYteUE1WFdCdmpYTlR4VGpsdjg0bmd2RzdVbDZxZElWSk1Xc1NkODlRSF9QN2dtdENhMExB?oc=5","date":"2019-08-12","type":"pipeline","source":"Fierce Pharma","summary":"Teva's Cephalon to ink $65.8M class-action settlement in Provigil pay-for-delay suit after judge's OK - Fierce Pharma","headline":"Teva's Cephalon to ink $65.8M class-action settlement in Provigil pay-for-delay suit after judge's OK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPY1RxTFQ1V1E5Z2Zob1BTanFQTjhudWFhRXpKbkdNeXREbGtxTXNRR05wbUdUT01nNFltZWN0bG12dlZiMGhKNXFOa1Z4Q3JlRFM4cmZ6RndxeTVOMHN0eFE0X05Yc2VmVE1fbUFhb1NBbndmWGNKbC15RF9xd09XVkhpTTZlUWx2WUlfdEdPY2h3SnBHcWRWWmE2QjlqMXFxZnRwNldFNF8wUdIBrwFBVV95cUxPcUlCT2Y3TFJ3LWdNdGdNN0V6LTFLc3pKV3JvRkdRbnZ2ejUxd2xBNHRVZlZXMU9aSTQyTnlOX3JSdVk0VEE4RUhjS1A3U29VU1lvR0Z6aXVfX04zYld1Y1NtVGE5ODIxVjNwRnhydkhrVFROVjZjM2paM3kycWI5c2JoZ2NwekNBd0dBOW1Cb09OUEJfdllEaVk2eHM4dThrU2s3VFJiMHp6QkZSTWo4?oc=5","date":"2019-06-28","type":"pipeline","source":"CBS News","summary":"Lollipop made with powerful opioid fentanyl was illegally marketed, ex-pharma rep says - CBS News","headline":"Lollipop made with powerful opioid fentanyl was illegally marketed, ex-pharma rep says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNbGh1N2NHWWxUeFpMY0ZFaEhCUGtWS1VSeHdlQm5od0lETkNZYmh4NzRGay01UEVjVHJua0VTS1dRRnB4dFFrbmVQejVhZ2djeFVIQmZrUTdfVWU2WlhRTDduMUoxUU85WUhNazFXTTBIOEJrQVdXMkx4NkxkYWd1UEdHeDl5WWY4cFZJMWN2WlU4ZnQwYXo3LS1CYmpjY0M4R3hUQjZZNlVncjdpZjVHMmVRVmgyVXZTOGc?oc=5","date":"2015-12-07","type":"pipeline","source":"VISTA.Today","summary":"Teva Pharmaceutical, Owner of Frazer's Cephalon, Forms Joint Venture With Japanese Drug Firm - VISTA.Today","headline":"Teva Pharmaceutical, Owner of Frazer's Cephalon, Forms Joint Venture With Japanese Drug Firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNUmp3RDBxRmZfY19qRklnMGNianhPVEpZc2VGNVdsM2tTYktFSTZqV0syakJyVGQzaExLemdKRTdxMTJaQkdaR2hUUGJhZFdVM01WTm5uNmlmZzJva0lRTkR6YXlXVDZvRWFUNENKRGN3aHRXTW5yLWJMeHJVMzJOX2s5VUFNX3FTR2NwNUo2VzNrd0l1T01ZQTI3eC1wQnF0cnBJZF93d3RFR3RwQUtQZEtacw?oc=5","date":"2015-11-05","type":"pipeline","source":"BioPharma Dive","summary":"AstraZeneca & Teva’s Cephalon to pay feds, states $54M for alleged rebate fraud - BioPharma Dive","headline":"AstraZeneca & Teva’s Cephalon to pay feds, states $54M for alleged rebate fraud","sentiment":"neutral"},{"date":"2015-03-27","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"date":"2011-11-14","type":"earnings","source":"SEC EDGAR","summary":"SC 13D filed with SEC: SC 13D","headline":"SC 13D Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOVHB2R1BlS2QxU2F3aXc4emxWX0hlbFpQVkNpWWRxOXZrdWdhdTZGMEV0VzdHQ3F0elNQM0N0VUJiNXlGQUdnb3VXSFpsTEZGbi1WN1NlUmMxT3lKSnpCajFOb1NHRDBDMjMxUWJzckNaQmVCSWNhMmxGX1NLakEwbmJPdDhUT2hsTW5PejM1T0pFRFllV3YtR0NOTjRvdw?oc=5","date":"2011-05-04","type":"pipeline","source":"Chemistry World","summary":"Teva sidelines Valeant with $6.8bn Cephalon bid - Chemistry World","headline":"Teva sidelines Valeant with $6.8bn Cephalon bid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBLckhDaVU5djc0aHk1cjUtYU53QlZYNmFiR2JBalliUjRKeTNaTUhSX0J6aWExXzN4R2laY3pvWjZHcmM2dGl4cmZMeWtVWGhvYlNid3BUZ0VIVklkNWZnbTFmZFNJdGNlcmhjNm9nNlBXcEpPSWhrOWpBT3d1b1k?oc=5","date":"2011-05-03","type":"deal","source":"Drug Channels","summary":"What's Behind Teva's Cephalon Deal - Drug Channels","headline":"What's Behind Teva's Cephalon Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE1Ldll2Z1o4OVY2ODZwb2VUN2hWVm93UFVIVEd5c1J1UFp1OGdLQ2d4ajdJWXh0ZzlYVmtxR1R1bkJwV3ZaZFNXRUJieDc5VTVvckE3SWwxdmtzd0hWNC1USjBXMWY4eTZiNXNyVUlYejFtLVZXZWVqYTV3?oc=5","date":"2011-05-02","type":"deal","source":"cen.acs.org","summary":"Israel's Teva Will Acquire Cephalon - cen.acs.org","headline":"Israel's Teva Will Acquire Cephalon","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_2":3,"phase_3":3,"marketed":5},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":2811057000,"revenuePeriod":"2010-12-31","revenueHistory":[{"value":2811057000,"period":"2010-12-31"},{"value":2192308000,"period":"2009-12-31"},{"value":1974554000,"period":"2008-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":425745000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":4891833000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}